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ABSTRACT 
 
Balanarasimha, Madhumitha. M.S., Department of Biochemistry and Molecular Biology, 
Wright State University, 2011. Structural and Functional Alteration of Full Length 
PPARα and LXRα by Fatty Acids and their Thioesters. 
 
 
 
Peroxisome proliferator-activated receptors (PPAR) and liver X receptors (LXR) 
are known to play important roles in fatty acid metabolism, interact with each other, and 
function as heterodimeric partners.  Although previous studies indicate that PPARα is 
activated by long chain fatty acyl-CoA thioesters (LCFA-CoA) and polyunsaturated fatty 
acids, little is known about the effects of these ligands on the function or interaction of 
PPARα and LXRα.  In this study, hPPARα and hLXRα were shown to directly interact 
by circular dichroism, fluorescent binding assays, and co-immunoprecipitation.  Further 
experiments suggested that although fatty acids resulted in small structural changes, they 
significantly altered binding affinities; while LCFA-CoAs decreased the binding 
affinities, no observable trend was seen with respect to the number of carbon atoms or 
bonds.  In addition, transactivation assays in the presence of certain fatty acids suggested 
that the combination of PPARα and LXRα increased the activity of the PPARα regulated 
gene – ACOX, while downregulating the LXRα regulated gene SREBP.  As high levels 
of fatty acids are associated with certain metabolic disorders and also serve as natural 
ligands for PPARα, changes in structure and/or interaction between PPARα and LXRα 
may have significant effects on the normal functioning of a cell.  
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I. INTRODUCTION 
 
The rising prevalence of diabetes and some of its related diseases, such as 
cardiovascular disease and stroke, are of growing concern.  According to statistics from 
the Center for Disease Control, diabetes, stroke and cardiovascular diseases are among 
the top ten causes for death in the United States [1].  Records from the National Institute 
of Diabetes and Digestive and Kidney Diseases state that diabetes affects about 9% of the 
U.S. population of all ages, and also shows that at least two out of three people with 
diabetes suffer from a heart attack or stroke [2] which is commonly caused due to 
elevated levels of lipids and accumulation of fats.  The tight regulation by certain 
proteins/nuclear-receptors/transcription-factors that regulate genes involved in fatty acids 
and lipid metabolism are of utmost importance in maintaining energy homeostasis, 
thereby preventing or controlling such situations.  
 
Nuclear Receptors 
 
Nuclear receptors are a class of ligand-activated transcription factors found in the 
interior of the cell that are able to recognize and regulate the expression of genes 
involved in energy homeostasis, metabolism, development and reproduction in response 
to molecules such as retinoid-, steroid- and thyroid-hormones [3, 4].  In addition to these 
hormones, a number of other molecules such as sugars [5], amino acids, lipids, and bile
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acids also act as ligands and regulate the transcription of such genes [6] [7].  While a 
majority of the ligands have been identified for these nuclear receptors, some of the 
endogenous ligands are still unknown and therefore these receptors are called orphan 
receptors [8].  
 
The initial discoveries of several nuclear receptors in the late 1980s  including 
retinoid X receptor (RXR) by Ron Evan’s group [9] and 9-cis retinoic acid receptor 
(RAR) by Pierre Chambon’s group [10], followed by other receptors such as PPAR, 
LXR, and farsenoid x receptor (FXR), can be attributed to the emergence of this class of 
orphan nuclear receptors, which paved the way to unravel some of the novel ligands now 
known [11].  Nuclear receptors were originally classified based on their ability to bind to 
DNA and ligands.  However, a more recent classification is based on sequence similarity 
classifying the receptors into six subfamilies: NR1 to NR6 with several subgroups among 
them [12].  Nuclear receptors have the ability to bind to specific sites on DNA called half 
sites of the hormone response elements (HRE) as monomers, homodimers or 
heterodimers [13].  The HREs can be further classified into direct-, indirect- and 
inverted-repeats [14] located in the 5’ region of the target genes commonly closer to the 
promoter, and are composed of a set of repeating nucleotide sequences that are separated 
by either one or more nucleotides [12].  While some of the receptors, such as PPAR, 
LXR, and RXR, are activated upon ligand binding, a few receptors such as the 
constitutive androsterone receptor (CAR) are ligand-independent and are constitutively 
active [11].  However in the case of a ligand-dependent nuclear receptor, ligand binding 
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either upregulates or downregulates the target genes leading to activation or inactivation 
of a given pathway.  
 
Structure of Nuclear Receptors 
 
Nuclear receptors are generally composed of 5 motifs: an NH2-terminal A/B 
domain, a DNA binding domain (DBD), a hinge region, a ligand binding domain (LBD) 
and a C-terminal domain [4].  
 
The NH2-terminal domain varies among species with respect to both size and 
sequence and displays specificity with reference to the species they identify and 
sequences that they bind to [15].  The A/B domain, which also contains a ligand-
independent activation function (AF-1), is responsible for the specificity among the 
different isoforms of a nuclear receptor and plays a key role in activation of these 
receptors in either a ligand-dependent or ligand-independent fashion [15].  Adjacent to 
this A/B domain is the conserved DBD which aids in the binding of the receptor to 
specific sites on the DNA called the HRE.  The DBD is composed of two zinc-fingers 
bonded to two pairs of cysteine residues [16]; one of which is located in the proximal-box 
(P-box) responsible for recognition of sites on the HRE and binding them with high 
affinity; and the second in the distal-box (D-box) that mediates dimerization of receptors.  
Upon recognition and binding to the DNA, these receptors can function either as 
activators (i.e. in transcribing the genes that the nucleotide codes for) or as repressors of 
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the genes.  The region between the DBD and the LBD acts as a hinge, and allows 
changes in conformation upon ligand binding.  The hinge region is also thought to have 
protein-protein interaction sites; however the actual function is still unknown.  
 
The LBD, which is mainly comprised of 11 to 13 alpha helices, forms a large 
hydrophobic pocket where it accommodates the ligand and undergoes conformational 
changes after being bound [17].  While studies have shown that the LBDs of most 
receptors are similar structurally, the sizes vary among receptors.  For example; each of 
the three isotypes of PPAR have a large LBD pocket that ranges between 1300-1400 Å3 
[17-20] which accommodates a variety of natural endogenous, as well as synthetic 
ligands, while the LBD of LXR isotypes can accommodate ligands only as big as 400 Å3 
[21].  Finally, the other end of the receptor, which is the C-terminal region, also called the 
F domain, contains an activation domain called the activation factor-2 (AF-2), which is 
responsible for ligand dependent activation and confers ligand specificity.   
 
PPAR 
 
PPARs belong to the class of ligand activated transcription factors of the NR1C 
subfamily of receptors [22], similar to the vitamin D receptor, thyroid receptor and 
retinoic acid receptor that also belong to the NR1 subfamily.  While the phenomenon of 
peroxisome proliferation was first seen in the 1960’s as a response to drugs such as 
fibrates in rodents [23], successful cloning of the PPAR gene from a mouse liver did not 
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occur until 1990 [24].  Since the discovery of this receptor that resulted in peroxisome 
proliferation, now known as PPARα [25], two other isotypes – PPARβ and PPARγ were 
also discovered  and cloned by the Wahli group [24].  However, the nomenclature for the 
two isotypes, PPARβ and PPARγ, can be considered as a misnomer since peroxisome 
proliferation is not seen in either of these two subtypes [25, 26].  The PPAR isotypes (α, 
β and γ) are expressed in different tissues based on their functions.  For example; PPARα 
is expressed most predominantly in the liver, heart and kidneys that require a lot of 
energy for their metabolic functioning.  Further, PPARγ is expressed in white adipose 
tissue, spleen and large intestine and the beta isotype is found ubiquitously.  
 
PPARs play an important role in a number of physiological functions, including 
metabolism of fats and sugars such as glucose [27, 28], cellular proliferation and 
differentiation [29], and also in inflammation [30].  Therefore, PPARs are implicated in a 
number of disorders including obesity, diabetes, cardiovascular diseases, atherosclerosis 
and cancer [31].  Many endogenous and exogenous ligands play a role in activating the 
receptor, which in turn regulates its’ target genes.  For example, drugs such as fibrates, 
roziglitazones and thiazolidinedione are exogenous ligands of PPARγ [32, 33], whereas 
naturally occurring fatty acids, eicosanoids and also fibrates act as PPARα ligands [34].  
Upon ligand activation, PPARα regulates genes including those coding for acyl-CoA 
oxidase (ACOX), liver-fatty acid binding protein (L-FABP) and carnitine palmitoyl 
transferase (CPT1A), which function in fatty acid metabolism, transport of LCFAs in 
liver and transport of LCFAs across the mitochondrial membrane respectively.  
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As any other nuclear receptor, PPARs also have an N-terminal A/B domain that is 
highly species specific and perhaps account for the differences that exist among the 
different species.  For example, peroxisome proliferation seen in rodents as a response to 
fibrates is not seen in humans [35].  PPARs are known to heterodimerize with other 
receptors such as RXR [36] and thyroid receptor (TR) [37] at the LBD and DBD domain 
[38] to form an active complex which then binds to the DNA to control gene expression 
by interacting with specific sites on the DNA response elements such as peroxisome 
proliferator response elements (PPRE) located upstream of target genes.  In addition to 
dimerization, binding of ligands such as fibrates and long chain fatty acids that cause a 
change in the conformation, also play a role in the activation of the nuclear receptor 
complex [39].  For example, PPARα activation can regulate the function of ACOX gene 
coding for the protein – acyl CoA oxidase, which is one of the first enzymes of fatty acid 
beta oxidation. ACOX aids in the conversion of acyl-CoA to trans-Δ2-enoyl-CoA [40].   
 
LXR 
 
Liver X receptor, commonly known as the cholesterol sensor [41, 42], is involved 
in regulating transport and metabolism of sterols and fatty acids and therefore plays a 
critical role in lipid homeostasis.  The two isotypes of LXRs that have been identified -
LXRα and LXRβ, also belong to the NR1H family of nuclear receptors and are known to 
share a sequence similarity of about 77% in both the DBD as well as the LBD [42, 43].  
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While compounds such as oxysterols, oxidized derivatives of cholesterol, were first 
identified as potent ligands, several other cholesterol derivatives including 24(S)-
hydroxycholesterol, 22(R)-hydroxycholesterol and 24(S),25-epoxycholesterol were also 
found to serve as potent ligands of LXRα [44, 45].  While LXRα is predominantly 
expressed in liver, intestine and adipose tissue [46], the beta form lacks tissue specificity 
and is expressed in almost all tissues [47, 48].  
 
LXRs are also involved in glucose [49] and cholesterol homeostasis [50], 
inflammation [51], and atherosclerosis [42].  LXRs can form heterodimers with other 
nuclear receptors such as RXR and bind to response elements known as Liver X receptor 
response elements (LXRE) to regulate a number of genes such as the sterol regulatory 
element binding protein (SREBP) [52, 53], fatty acyl synthase (FAS) and glucose 
transporter (GLUT1).  As the name suggests, SREBP codes for a binding protein that 
regulates the synthesis of sterols (cholesterols) and fatty acids, and maintains the levels of 
intracellular lipids.  Thus LXR, like PPAR, determines the fate of the molecules to which 
it binds.  
 
Why PPARα and LXRα?? 
 
PPARα and LXRα regulate transcription of genes involved in metabolism, and 
therefore their normal functioning is important in maintaining energy homeostasis.  
PPARα binding to fatty acids, fatty acyl thioesters, and eicosanoids facilitates fatty acid 
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uptake, transport and oxidation.  LXRα binds oxysterols and endogenous cholesterol 
derivatives and regulates cholesterol transport, genesis and degradation.  Both PPARα 
and LXRα function as heterodimeric partners with the retinoid X receptor alpha (RXRα) 
in order to control gene regulation.  Previous studies have suggested that PPARα and 
LXRα themselves can function as heterodimeric partners [54], but the significance of this 
finding is unclear.  Two separate studies by Ide et al have shown that a crosstalk exists 
between PPARα and LXRα in regulating fatty acid metabolism. The study suggests that 
PPARs suppress the activity of SREBP-1c gene by inhibiting the signaling pathway of 
LXR and that LXRs inhibits PPAR signaling pathway thus suppressing its activity [54, 
55].  However, it is not known whether the inhibition occurs due to a direct or an indirect 
interaction between the two nuclear receptors.  
 
Also, it is not known if fatty acids or fatty acyl thioesters promote or inhibit 
PPARα and LXRα heterodimer formation.  Most studies involving these receptors have 
used either truncated or tagged proteins, and therefore not much is known about the 
activity and effects of full-length proteins.  Moreover, the effects of nuclear receptor 
activation by ligands differ among species (eg. peroxisome proliferation induced by 
PPARα agonists are only seen in rodents and not in humans) and very few studies have 
utilized full-length human version of these receptors.  Any change in the receptor’s 
structure can result in a change of its function leading to metabolic disorders such as 
diabetes, obesity, atherosclerosis and cardiovascular diseases.  Thus, it becomes 
imperative to study the effects of various putative ligands on the human, full-length 
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versions of these receptors.  The objective of this study was to look at the effects of 
saturated and unsaturated fatty acids and fatty acyl thioester derivatives on the interaction 
of human PPARα and LXRα. 
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II. GOALS AND HYPOTHESES 
 
The three goals of this study were: firstly, to examine whether or not full-length 
hPPARα and hLXRα directly interact with each other; secondly to study the effects of 
LCFAs and LCFA-CoAs on the interaction of hPPARα and hLXRα; and finally to study 
the effects of LCFAs and LCFA-CoAs on the function of hPPARα and hLXRα regulated 
genes.  
 
 In order to test the goals, the following hypotheses were made. The first being, 
full length recombinant hPPARα and hLXRα directly interact with high affinity; 
secondly fatty acids and/or fatty acyl-CoA affect the interaction between the proteins, and 
finally, fatty acids and/or fatty acyl-CoA that affect the interaction will have an effect on 
the activity of the two proteins.  
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III. MATERIALS AND METHODS 
 
Protein Expression in Bacteria 
 
Full-length, tagged recombinant human PPARα and LXRα proteins were 
expressed in Escherichia coli, purified using affinity chromatography, and tags were 
removed by on-column cleavage.  The plasmids encoding the recombinant proteins, 417 
amino acid long PPARα and 453 amino acid long LXRα were individually cloned into  
separate pGEX-6-P3 bacterial expression vectors which were modified to include an N-
terminal 6X histidine tag between the start codon and the Glutathione S transferase 
(GST) tag.  These plasmids were produced in the Hostetler lab by Dr. S. Dean Rider, Jr. 
Growing conditions were first tested in order to optimize the purity and yield of the two 
proteins.  Rosetta cells derived from a BL21 strain (Novagen, Philadelphia , PA) were 
transfected with the ampicillin-resistant plasmid pHH55 (Figure 1A), which codes for 
full-length His6-GST tagged- hPPARα was used to express the protein, and a DNAK 
mutant derived from a K12 strain (JW0013, E. coli Stock Center) transfected with the 
ampicillin-resistant plasmid pHH3-1 (Figure 1B) was used to express full-length hLXRα.   
 
For hPPARα, an overnight culture was grown in 100ml Luria Bertani (LB) media 
(Becton Dickson) containing 0.1mg/ml ampicillin, 0.2mg/ml chloramphenicol and 10% 
glucose at 30oC and 200 rpm.  The following day, this 100ml overnight culture was 
subcultured into 1L of LB at 37oC for up to 3 hours until an OD600 of 1.5-1.8 was 
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obtained.  After the desired OD was reached, protein expression was induced with 0.1M 
IPTG for 4 hours at 16oC.  The cells were then pelleted using an Avanti-J26 XPI 
centrifuge at 8500rpm for 10minutes at 4oC, and 100mM PMSF was added to the pellet 
to stop the action of proteases.  
  
For hLXRα, an overnight 40 ml LB (Sigma Aldrich) culture was grown at 37oC 
and 175 rpm in the presence of 0.1mg/ml ampicillin, 0.2mg/ml chloramphenicol and 10% 
glucose.  The overnight culture was then subcultured into 1L of pre-warmed LB media 
and grown for 2 hours at 30oC at 200 rpm, following which the temperature was turned 
down to 16oC and continued to grow for 2 more hours.  The culture was then induced 
with 0.1M IPTG for 4 hours at 16oC and pelleted using an Avanti-J26 XPI centrifuge at 
8500 rpm for 10minutes at 4oC.  Again, 100mM PMSF was added to the pellet to stop the 
action of proteases.  The pellets were then stored in -80oC for further protein purification. 
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FIGURE 1:  Schematic representation of plasmid DNA coding for full-length hPPARα and 
hLXRα with 6His-GST tag. (A) The cDNA encoding the complete hPPARα with the amino 
acids 1-473 was cloned into a pGEX-6-P3 bacterial expression vector which was modified to 
include an N-terminal 6X histidine tag between the start codon and the Glutathione S transferase 
(GST) tag. This construct was then expressed in the BL21 Rosetta strain of Escherichia coli and 
purified by affinity chromatography using a GST affinity column.  (B) The cDNA encoding the 
complete hLXRα with 453 amino acids was cloned into a pGEX-6-P3 bacterial expression vector 
which was modified to include an N-terminal 6X histidine tag between the start codon and the 
Glutathione S transferase (GST) tag. This construct was then expressed in the DNAK mutant 
strain of Escherichia coli and purified by affinity chromatography using a GST affinity column.   
 
 
 
 
A B 
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Protein Purification using Affinity Chromatography 
 
On the day of purification, the pellets were resuspended in 10mls of 2X L&C 
buffer (40mM Tris, pH 8.0, 0.35mM NaCl and 20% glycerol) [56] SDS-PAGE analysis 
was containing 1mM DTT and 2mM EDTA and 10mls 2X protease inhibitor 
SIGMAFAST™ protease inhibitor cocktail tablet, EDTA-free (Sigma-Aldrich, St. Louis, 
MO) resuspended in 2X L&C buffer.  The cell suspension was sonicated on ice six times 
for 30 seconds, with 30 second intervals between each sonication, at an amplitude of 50% 
with a Sonic Dismembrator (Fischer Scientific).  The cell debris was pelleted by 
centrifugation using an Avanti-J26 XPI centrifuge at 10,000 rpm for 20 minutes.  
 
The cell lysate obtained after pelleting the cell debris was completely circulated in 
the affinity chromatography column with glutathione sepharose resin at the flow rate of 
0.1ml per minute and was washed three times; first with 2mls of 1X L&C buffer (20mM 
Tris, pH 8.0, 0.175mM NaCl and 10% glycerol), followed by 5mls of ATP wash buffer 
(2X L&C buffer, 10mM ATP and 50mM MgCl2), and finally with 10mls of 1X L&C 
buffer (containing 1mM DTT and 2mM EDTA) in order to remove any unbound protein 
from the column.  Following the three washes, a PreScission protease mix (1 ml 1X L&C 
containing 1mM DTT and 0.5mM EDTA and 120µg protease) was circulated through the 
column for 4 hours at 4oC, after which the full-length untagged recombinant protein was 
eluted.  Additional elutions of 1ml (of 1X L&C containing DTT and EDTA) were 
collected to completely remove any remaining cut protein from the column.  
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Protein Estimation 
 
The protein content in the elute was analyzed using both the Bradford assay and 
the molar extinction coefficient, which defines the strength of absorption of light at a 
given wavelength by the substance, based on its molar concentration.  The sample (5µl) 
was mixed with 195µl of Bradford reagent (Bio-Rad Inc.) and standards were set up 
using IgG protein standards (Sigma Aldrich), ranging from 0.1mg/ml to 1mg/ml of IgG.  
The absorbance was read at 595 nm using a plate reader in spectrophotometer (SAFIRE2 
DECAN), a standard curve was generated using the IgG concentration, and protein 
concentrations were calculated by extrapolating the absorbance values of the samples 
against the standard curve of IgG.  The concentration of the protein-dye complex was 
calculated by factoring in the protein concentration and molar extinction coefficient of 
the protein and the dilution factor.  
 
SDS-PAGE & Western Blot Analysis  
 
SDS-PAGE analysis was conducted following protein estimation, for separation 
and visualization of the protein band corresponding to its molecular weight of about 
50kDa (for both hPPARα and hLXRα).  The protein elute (10µg) was mixed with 2X 
sample buffer (10%SDS, 2M Tris, pH6.8, 1.2% bromophenol blue, 10% glycerol), heated 
at 90oC for 3 minutes and loaded onto a 12% SDS-PAGE gel using standard techniques.  
Prestained Benchmark Protein markers (Invitrogen) were loaded together with the protein 
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samples and the gel was run at constant amps for 60 minutes.  Following the separation 
using SDS-PAGE, the gel was stained using Coomassie blue, destained in 7.5% acetic 
acid and visualized using the Fujifilm LAS 4000 imaging system.  However, for western 
blot analysis, the resolved gel was directly used to transfer the proteins onto 
nitrocellulose membrane using a BioRad electrotrans blot apparatus overnight at 30 volts 
and 4oC per the manufacturer’s recommendations.  Following the transfer, the blots were 
blocked with 3% BSA in TBST overnight at 4oC and later incubated with primary 
antibodies using anti-mouse monoclonal PPARα antibody (MA1-822, ThermoScientific) 
and anti-goat polyclonal LXRα (PA1-330, ThermoScientific) at a concentration of 
1µg/750µl in 1% BSA in TBST for PPARα and LXRα respectively for 1 hour at room 
temperature on a rocker.  After treating with primary antibodies, the blots were washed 
thrice using TBST for 5 minutes and then treated with respective secondary antibodies at 
a concentration of 1µg/10ml in 1% BSA in TBST for 1 hour at room temperature.  The 
blots were again washed thrice with TBST with 5 minute incubation each time in order to 
remove any unbound antibody.  Finally, a 15 minute wash with TBS was performed, after 
which the blots were developed using alkaline phosphatase reagent and imaged using the 
Fuji Film LAS-4000 imaging system. 
 
Circular Dichroism  
 
A JASCO-815 spectropolarimeter was used to analyze the structure of hPPARα 
and hLXRα proteins individually, and also as a mixture to determine any possible 
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interaction between the two proteins as previously described for mouse PPARα by 
Hostetler et al [57].  Further, circular dichroic spectra of the two proteins in the presence 
and absence of both saturated and unsaturated fatty acids and their CoA thioesters were 
taken to determine their effects on the structure of hPPARα and hLXRα.  The fatty acids 
Palmitic acid (C16:0), Oleic acid (C18:1), Linoleic acid (C18:2) and Eicosapentaenoic 
acid (EPA) (C20:5) and their CoA thioesters; Palmitoyl CoA (C16:0-CoA), Oleoyl CoA 
(C18:1-CoA), Linoleoyl CoA (C18:2) and EPA-CoA (C20:5-CoA) were used in this 
experiment.  An average of 5 scans at the rate of 50nm/min was acquired in order to 
account for any errors and a minimum of three repetitions were conducted for accuracy, 
with a D.I.T of 1 second and a bandwidth of 2nm.  While stock solutions of each fatty 
acid were diluted in 50% ethanol, the final ethanol concentration in each reaction was 
less than 0.05%. The protein sample was suspended in a low salt buffer (0.5mM HEPES 
containing 0.005mM EDTA, 5mM KCl and 0.04% glycerol) to ensure that the 
absorbance due to salt does not interfere with the signal from the proteins.  Appropriate 
controls with dialysis buffer and ethanol were also run to account for any changes caused 
due to salt and ethanol.  A far UV scan from 260nm to 185nm was read to determine the 
secondary structure of the proteins.  For optimum absorbance readings, both hPPARα and 
hLXRα were used at an amino acid concentration of 0.0002M.  For this amino acid 
molarity, 0.42µM hPPARα, 0.44µM hLXRα was used in absence and combination with 
0.5µM fatty acids and their CoA thioesters when the spectra of two proteins were read 
individually with the ligands.  However, when the spectra of a mixture of hPPARα and 
hLXRα with the ligands were read, the amino acid concentrations were adjusted to a total 
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of 0.0002M by using exactly half the concentration (i.e. 0.21µM hPPARα, 0.22µM 
hLXRα).  CD spectra were analyzed using CONTIN program and the SDP42 (185-
240nm) database of CD Pro software [58].  As a negative control, CD spectra of 0.40µM 
of hGR (glucocorticoid receptor purchased from ThermoScientific), 0.44µM of hPPARα, 
and 0.2µM of hGR + 0.22µM of hPPARα were obtained and compared to the average 
spectrum of hGR and hPPARα.  The CD spectrum of a mixture of each combination of 
proteins was compared to the calculated average of the individual proteins’ spectra in 
order to determine whether structural changes occurred, suggesting a direct interaction 
between the proteins.   
 
Protein-Protein Binding Assays/ Ligand Binding Assay 
 
Binding assays of hPPARα and hLXRα were conducted using a PC1 fluorometer 
(ISS, Champaign, IL) to determine the binding affinities between the hPPARα and 
hLXRα.  In order to obtain binding affinities (in terms of Kd), recombinant hPPARα was 
fluorescently labeled with a commercially available Cy5 Maleimide mono-reactive dye 
kit (Amersham, Pittsburgh, PA) that labels sulfhydryl groups, such as those on cysteine 
molecules present in the protein molecule.  For optimum labeling, 1mg of hPPARα in 
buffer (Table 1) with a pH8.0 was incubated with Cy5 dye for 1 hour on a rotor and 30 
minutes on the bench top at room temperature.  The labeled protein was then separated 
from free dye by size exclusion chromatography in PBS, pH 7.4, and the molar 
concentration of the protein was estimated by Bradford assay, and the dye concentration 
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was measured by spectrophotometry using the molar extinction coefficient of the dye at 
650nm.  The dye to protein ratio determined using the molar concentrations of the protein 
and the dye resulted in 3 dyes labeled per protein molecule.  Labeled hPPARα was 
titrated against an increasing concentration of unlabeled recombinant hLXRα, and was 
initially blanked using PBS.  During the titration, between each addition, a 3min stir time 
was given for proper mixing and to allow equilibrium to be reached.  25nM Cy5-
hPPARα, excited at 650nm was titrated against 0nM-250nM range of hLXRα, and the 
emission scanned from 660nm to 700nm yielded a peak around 670nm corresponding to 
the fluorescence emission, which was further used to calculate the binding affinity.  
Binding curves were then generated by non-linear regression analysis using the ligand 
binding function in Sigma Plot (SPSS, Chicago, IL).  A double reciprocal plot was 
generated as previously described to determine the number of binding sites on the protein 
molecule [39].  In order to confirm that the binding of the two proteins was not just an 
artifact and not the effect of Cy5 dye, hLXRα was labeled with Cy3 dye and titrated 
against unlabeled hPPARα.  The binding affinity of Cy3 labeled hLXRα with a dye to 
protein ratio of 2:1 was titrated against 0nM to 250nM of unlabeled hGR.  
 
The binding affinity between hPPARα and hLXRα was also determined in the 
presence of the four LCFA and LCFA-CoA (mentioned in the CD experiments).  In order 
to find the Kd, 25nM of both Cy5- hPPARα and the ligands were first mixed and then 
titrated against an increasing concentration of hLXRα (0nM to 250nM).  Binding affinity 
of hPPARα and hLXRα were then determined in a similar way as described above.   
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TABLE 1. Composition of dialysis buffer 
CHEMICAL NAME CONCENTRATION 
HEPES buffer 10mM 
EDTA 0.1nM 
DTT 0.4mM 
KCl 100mM 
Glycerol 10% 
 
Co-Immunoprecipitation 
 
Liver samples were extracted from 8-10 week old male C57BL/6J mice obtained 
from Jackson Laboratory.  Mice were euthanized by CO2 asphyxiation, and cervical 
dislocation was performed to ensure death per Wright State University LACUC approved 
protocols.  Liver samples were extracted, chopped with a razor blade into fine pieces in 
4mls of PBS, pH 7.4 and homogenized by sonication.  The homogenate was then 
centrifuged at 10,000 rpm at 37oC for 5 minutes (Eppendorf Centrifuge 5424).  Pierce 
CoIP kit (ThermoScientific – 26149) was used to perform immuno-precipitation reactions 
per manufacturer’s recommendations.  This kit covalently links the antibodies to the 
resin, thereby preventing antibodies from being observed in the elutes.  Total proteins 
from liver homogenates were quantified by Bradford assay and 400ul of liver sample 
containing 4mgs of total protein was incubated for 2 hours at room temperature with 
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resins coupled with PPARα and LXRα antibodies.  A resin with no antibodies coupled to 
it was also used as a control. The resin was washed with wash buffer containing 1M NaCl 
and eluted using elution buffer provided in the kit.  The elutions of about 50µl obtained 
from each resin was mixed with loading dye (0.3M Tris.HCl, 5% SDS and 50% 
glycerol), loaded on to a 12% SDS-PAGE gel for protein separation, and transferred to 
nitrocellulose membrane by electroblotting method for Western blot analysis.  Blots were 
treated as explained above with anti-mouse monoclonal PPARα (ThermoScientific MA1-
822) and anti-rabbit polyclonal LXRα (ThermoScientific: PA1-330).   
 
Transactivation Assay 
 
HepG2 cells (ATCC) that were 85-90% confluent were seeded onto four 24-well 
culture plates and grown overnight at 37oC in a humidified CO2 incubator as previously 
described [5].  The media in each well was replaced by 1ml of low-serum Eagles 
Minimum Essential Media (EMEM), and transfected with 0.4µg of respective plasmids.  
For overexpression of hPPARα and hLXRα in mammalian cells, pSG5 (Stratagene, La 
Jolla, CA), a eukaryotic expression vector containing an SV40 early promoter and 
polyadenylation signal that promotes expression in cells, was utilized.  The DNA 
sequences encoding full length hPPARα and hLXRα were amplified from the bacterial 
expression vectors (described in protein expression in bacteria section) by PCR using the 
following the primers: CATCGGA TCCACC ATG GTG GAC ACG GAA AGC CCA 
and CCG GGA GCT GCA TGT GTC AGA GG (hPPARα), CATCGGA TCCACC ATG 
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TCC TTG TGG CTG GGG GCC CCT GTG and CCG GGA GCT GCA TGT GTC AGA 
GG (hLXRα).  While a Bam HI / end-filled Sal I fragment was subsequently transferred 
into the multiple cloning site of pSG5 (Bam HI / end-filled Bgl II) to produce pSG5-
hPPARα plasmid, Bam HI / end-filled Xho I fragment was subsequently transferred into 
the multiple cloning site of pSG5 (Bam HI / end-filled Bgl II) to produce pSG5-hLXRα.  
These plasmids encoding hPPARα, hLXRα and/or the empty vector pSG5 were 
transfected into the HepG2 cells with Lipofecatmine™ 2000 (Invitrogen) in accordance 
with the manufacturer’s instructions.  Each of the four plates was transfected with: (i) 
pSG5-hPPARα, (ii) pSG5-hLXRα, (iii) a mixture of pSG5-hPPARα and pSG5-hLXRα, 
or (iv) the empty pSG5 plasmid as a control.  All four sets were also transfected with 
0.4µg of a basic luciferase reporter construct (pGL4.17, Promega, Madison, WI) 
containing 2.3kb of the ACOX promoter upstream of the firefly luciferase gene.  This 
plasmid was generated by amplifying the ACOX promoter region with the following 
primers ATGACTCTGTTTTCTATGACCT and GCTCCGAAGGTCAAGAAACT, and 
subsequently cloned into the pGL4.17 vector in the Hostetler laboratory by Mr. Dhawal 
Oswal.  ACOX is a gene known to be regulated by PPARα and if upregulated would 
result in high luciferase activity indicating a positive regulation, and conversely, a 
decreased luciferase expression corresponding to reduced ACOX expression.  In addition 
to this, all four sets were also transfected with 0.04ug of pRL-CMV plasmid (a eukaryotic 
expression vector for Renilla luciferase driven by the constitutive cytomegalovirus 
promoter CMV) as an internal control for transfection efficiency.  Following transfection, 
cells were incubated for 6-8 hours at 37oC in a humidified CO2 incubator and then the 
 
23 
 
media were replaced by serum-free EMEM media for 1 hour to allow excess fatty acids 
to be utilized.  The fatty acids were linked to BSA in order to facilitate their intake into 
the cells as previously described [59].  Four concentrations (1µM, 5µM, 10µM and 
20µM) of these BSA-linked ligands (palmitic acid, oleic acid, linoleic acid and EPA) 
were added to the cells and the cells were grown for 20 additional hours to examine the 
effects of ligands on the activity of PPARα, LXRα and a mixture of the two proteins.  
Similar concentrations of the known PPARα activator, clofibrate (Sigma Aldrich 
197777), were also used as a positive control [60].  The activity of firefly luciferase, 
normalized to Renilla luciferase that accounts for transfection efficiency, was determined 
using the dual-luciferase reporter assay kit (Promega,Madison, WI) and the sample with 
1µM clofibrate was arbitrarily set to 100%.  The luminescence was measured using a 96-
well Microlite flat bottom microtitre plate (Thermo) using the SAFIRE2 TECAN (Tecan 
Systems, Inc, San Jose, CA) for measuring luminescence. 
 
Similar experiments were also conducted with a pGL4.17 plasmid encoding the 
SREBP-1c promoter, which was generated by amplifying the SREBP-1c promoter region 
with the following primers CGGTACCTCGAGCACTTGCAGGCTGGA and 
CGAGCTCGCCCCTAGGGCGTGCAGACG, and subsequently transferred into the Kpn 
I / Sac I sites of pGL4.17 in the Hostetler laboratory by Dr. S. Dean Rider, Jr.  SREBP, 
known to be regulated by LXR was also examined to determine the effects of ligands on 
the activity of PPARα, LXRα and also a combination of the two proteins.  The values for 
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SREBP were normalized and compared with the positive control (ACOX-Clofibrate) that 
was arbitrarily set to a 100%.   
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IV. RESULTS 
 
SDS-PAGE and Western analysis showed the presence of a 50kDa protein that 
corresponded to the size of full length hPPARα and hLXRα  
 
The full length recombinant proteins - hPPARα and hLXRα, purified using affinity 
chromatography, were run separately on 12% SDS-PAGE.  The gels showed a band at 
around 50kDa, corresponding to the size of hPPARα (Figure 2A) and hLXRα (Figure 
3A), which have a molecular weight of 52636Da and 51768Da respectively.  Further, 
western blot analyses using antibodies for PPARα (Figure 2B) and LXRα (Figure 3B) 
confirmed the identity of the 52kDa band, further indicating the purification of full 
length, untagged protein.  While the hPPARα gel shows a clear band at 52kDa and few 
lighter bands below, the corresponding Western also shows similar bands, suggesting that 
the other bands could be the degraded protein or a portion of hPPARα that was not 
completely translated.  Similarly, the hLXRα gel as well as the Western shows a clear 
band at 50kDa and a few higher bands, which can be the LXR-LXR heterodimer.  
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FIGURE 2: SDS-PAGE and a Western Blot showing full length hPPARα: (A) 12% SDS gel 
showing the 52kDa full length recombinant hPPARα protein purified by affinity chromatography 
using a GST affinity column.  The gel was stained using Coomassie blue stain and destained in 
7.5% acetic acid.  (B) A western blot showing the 52kDa hPPARα band developed using an anti-
mouse monoclonal antibody specific for the alpha isoform.   
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FIGURE 3: SDS-PAGE and a Western Blot showing full length hLXRα: (A) 12% SDS gel 
showing the 52kDa full length recombinant hLXRα protein purified by affinity chromatography 
using a GST affinity column, M – benchmark prestained marker (Invitrogen).  The gel was 
stained using Coomassie blue stain and destained in 7.5% acetic acid. (B) A western blot showing 
the 52kDa hLXRα band developed using an anti-rabbit monoclonal antibody specific for the 
alpha isoform.  
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Circular Dichroism of hPPARα and hLXRα demonstrated conformational changes 
and suggested possible interaction between the two proteins 
 
Circular dichroism, a spectrophotometric method used to determine the secondary 
structure of proteins, uses the principle of differential absorption of left and right 
circularly polarized light.  This method was used to examine the secondary structure of 
full-length hPPARα and hLXRα individually and also as a mixture.  While the CD 
spectra of hPPARα was characterized by a positive peak at approximately 190nm and 
two distinct negative peaks at 210nm and 220nm, the structure of hLXRα had a positive 
peak at 190nm and two small negative peaks at 210nm and 220nm (Figure 4); suggesting 
that LXRα has a less alpha helical structure. This was confirmed by examining the 
percent composition of each protein, which showed that each protein was also comprised 
of a considerable percentage of turns and unordered structures (Table 2).  Although 
hPPARα and hLXRα displayed slightly different spectra, these data suggested that both 
proteins have structure and that the purification process did not denature the proteins.   
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FIGURE 4: Circular dichroic spectra of hPPARα and hLXRα.  Circular dichroic spectra of 
0.42µM hPPARα alone (closed circle), showing a positive peak at 190nm and two negative peaks 
at 210nm and 220nm and 0.44µM hLXRα alone (open circle) showing one positive peak at 
around 190nm and two small negative peaks at 210nm and 220nm. 
 
 
TABLE 2. Secondary structure of hPPARα and hLXRα in the absence of ligands 
        Protein α-helix 
regular 
α-helix 
distorted 
β-sheet 
regular 
β-sheet 
distorted 
Turns          Unrd  
 H(r) % H (d) % S(r) % S (d) % T%          U%  
PPARα 7.2 ± 2.6 7.8 ± 0.9 21.2 ± 2 10.2 ± 1.1 17.7 ± 2 36.4 ± 3.5 
LXRα 5.8  ± 2.4 5.7  ± 0.6 20.4 ± 3.2 9.3 ± 1.5 15.6 ± 3.4 43.1 ± 5 
GR 0.7 ± 0.1 3.9 ± 0.2 24 ± 0.3 12 ± 0.7 19.6 ± 2 39.3 ± 2.7 
PPARα+LXRα (Exp) 5 ± 1.5 6.2 ± 1.4 17.3 ± 3 10.8 ± 3 23.4 ± 7 37 ± 6.2 
PPARα+LXRα (CA) 5.4 ± 1.7 6.3 ± 0.5 21.2 ± 2.3 9.2 ± 1.3 16 ± 2.8 41.4 ± 4.4 
PPARα+GR (Exp) 7.2 ± 1.8 7.1 ± 0.3 19.5 ± 2.2 8.2 ± 1.8 14 ± 4.2 43.8 ± 6.7 
PPARα+GR (CA) 4.5 ± 2.8 6 ± 0.4 19 ± 2.8 9 ± 2.4 14.6 ± 5 45.2 ± 7.4 
PPARα, peroxisome proliferator activated receptor-α; LXRα, Liver x receptor-α, GR, 
glucocorticoid receptor; Unrd, unordered 
Exp – experimental, CA – Calculated average  
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Furthermore, a mixture of hPPARα and hLXRα at equal amino acid molar 
concentrations underwent a change in conformation, and assumed a structure close to that 
of an alpha helix structure, however displaying one positive peak at 190nm and one 
distinctive negative peak at around 210nm, with a smaller peak at 220nm (Figure 5A).  
The change in the structure of the proteins can determine the possibility of either an 
interaction or no interaction, which is interpreted by comparing the actual (or 
experimental) spectra with the calculated average obtained by averaging the individual 
spectrum of the two proteins.  While a spectrum overlaying the calculated average 
suggests no interaction between the two proteins, a spectrum that is different from the 
calculated average suggests a possible interaction.  In this experiment the actual spectrum 
was slightly different from the calculated average, suggesting the probability of an 
interaction between the proteins.  Further, when equal concentrations of hPPARα and 
hGR were run as a control, the spectra representing the actual change overlapped the 
calculated average of the two spectra (Figure 5B) suggesting no interaction between the 
two proteins.  This was further substantiated by comparing the lack of significant 
differences in the percent compositions (Table 2). 
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FIGURE 5: Circular dichroic spectra of a combination of two proteins. (A) Circular dichroic 
spectra of hPPARα and hLXRα demonstrated a change in the secondary structure.  Circular 
dichroic spectra of a mixture of 0.21µM hPPARα and 0.22µM hLXRα (closed circle) and an 
average of hPPARα and hLXRα spectra (open circle) representing no interaction between the two 
proteins. (B) Negative control showing no interaction between hPPARα and hGR where the 
actual spectrum of hPPARα and GR (open circle) superimposes on the average of the hPPARα 
and hGR spectrum (closed circle).  
Exp – experimentally obtained spectra, CA – calculated average.  
 
Circular Dichroism of hPPARα and hLXRα in the presence of fatty acids and their 
CoA 
 
Circular dichroic spectra of the mixture of hPPARα and hLXRα were obtained in 
the presence of fatty acids and their CoA thioesters to examine their effects on hPPARα 
and hLXRα’s structural conformation and interaction. Conformational changes of 
proteins are very significant as they determine the function of the protein, and any change 
in conformation may result in folding of a protein in such a way that it can either promote 
or inhibit it’s interaction with other proteins, ligands, or DNA. In order to determine the 
effect of fatty acids or their CoA thioesters, several spectra were obtained.  First, the 
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experimental CD spectrum of each protein was obtained individually in the presence and 
absence of each fatty acid or fatty acyl-CoA.  Next, the experimental CD spectrum of a 
mixture of equal molar concentrations of hPPARα and hLXRα was obtained in the 
presence of each fatty acid or fatty acyl-CoA. Then the actual spectra obtained for a 
mixture of hPPARα and hLXRα in the presence of fatty acids or fatty acyl-CoA was 
compared to (i) the spectra of hPPARα and hLXRα in the absence of ligand, (ii) the 
calculated average of each protein in the presence of that particular ligand, (iii) the 
calculated average of hPPARα bound to ligand and hLXRα, (iv) the calculated average of 
hLXRα bound to ligand and hPPARα (Table 4 and Table 5).  An experimentally obtained 
spectrum similar to the one obtained from hPPARα and hLXRα in the absence of ligand 
would suggest that the ligand had no effect on the interaction between the two proteins 
(Figure 6A).  However, a spectrum similar to the calculated average of hPPARα and 
hLXRα the presence of ligand would suggest the inhibition of protein interaction due to 
the ligand (Figure 6B).  Further, spectra resembling the calculated average of hPPARα in 
the presence of ligand and hLXRα in the absence of ligand or hLXRα in the presence of 
ligand and hPPARα in the absence of ligand would suggest that the binding of the ligand 
to either of the proteins inhibits the protein-protein interaction.  However, a spectrum 
dissimilar to each of these comparisons would suggest a new conformation, most likely 
of all three components (hLXRα, hPPARα, and ligand).   
 
Circular dichroic spectra of hPPARα and hLXRα with a saturated fatty acid - 
palmitic acid (Figure 6A), were superimposable on the spectra of a mixture of hPPARα 
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and hLXRα in the absence of fatty acid, suggesting no conformational change and 
therefore proposing no effect of palmitic acid on the protein-protein interaction. 
However, its thioester form; palmitoyl-CoA (Figure 6B) displayed a significant change in 
conformation and lay on the average of the two spectra suggesting that the CoA thioester 
might interfere with the interaction between hPPARα and hLXRα and could potentially 
decrease the binding affinity.  
 
Oleic acid (Figure 6C) displayed a similar trend to that of palmitoyl-CoA by 
being superimposable on the spectrum  of the average of hPPARα and hLXRα suggesting 
a decreased interaction between the two proteins, while its CoA thioester (Figure 6D) 
showed a very small structural change indicating an effect of oleoyl-CoA on the 
interaction between the two proteins.  
 
In the case of linoleic acid (Figure 7A) and eicosapentaenoic acid (EPA) (Figure 
7C), two polyunsaturated fatty acids, both displayed a similar trend, where the average 
spectra almost overlaid on the mixture of the two proteins with ligand suggesting that 
linoleic acid and EPA possibly interfered with the interaction between the two proteins. 
Conformational changes observed with the CoA derivatives of both fatty acids - linoleoyl 
CoA (Figure 7B) and EPA-CoA (Figure 7D) were similar to one another suggesting that 
they could also interfere with hPPARα and hLXRα to prevent the two proteins from 
interacting.   
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FIGURE 6: CD spectra of a mixture of hPPARα and hLXRα in the presence and absence of 
fatty acids and their CoA thioesters. Far-UV spectra of a mixture of equal amino acid 
molarities of hPPARα and hLXRα in the absence of ligands (closed inverted triangles), a mixture 
of equal amino acid molarities of hPPARα and hLXRα in presence of ligand (closed circles), and 
the theoretically expected spectrum of the two proteins in the presence of ligand if no interaction 
occurred between hPPARα and hLXRα, obtained by averaging the spectrum of hPPARα plus 
ligand with the spectrum of hLXRα plus ligand (open circles).  Ligands include: (A) C16:0, (B) 
C16:0-CoA, (C) C18:1, and (D) C18:1-CoA. Each spectrum is a representative of an average of 
ten scans and is taken from three replicates.   
Exp – experimentally obtained spectra, CA – calculated average.  
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FIGURE 7: CD spectra of a mixture of hPPARα and hLXRα in the presence and absence of 
fatty acids and their CoA thioesters. Far-UV spectra of a mixture of equal amino acid 
molarities of hPPARα and hLXRα in the absence of ligands (closed inverted triangles), a mixture 
of equal amino acid molarities of hPPARα and hLXRα in presence of ligand (closed circles), and 
the theoretically expected spectrum of the two proteins in the presence of ligand if no interaction 
occurred between hPPARα and hLXRα, obtained by averaging the spectrum of hPPARα plus 
ligand with the spectrum of hLXRα plus ligand (open circles).  Ligands include: (A) C18:2, (B) 
C18:2-CoA, (C) C20:5, and (D) C20:5-CoA. Each spectrum is a representative of an average of 
ten scans and is taken from three replicates.   
Exp – experimentally obtained spectra, CA – calculated average.  
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TABLE 3. Secondary structures of hPPARα and hLXRα (corrected for solvent effect) in 
the presence of fatty acids and their CoA thioesters 
Protein α-helix regular 
α-helix 
distorted 
β-sheet 
regular 
β-sheet 
distorted Turns Unrd 
  H(r) % H (d) % S(r) % S (d) % T% U% 
PPARα + solvent 5.1 ± 1.6 6.5 ± 0.3 22.3 ± 2.3 9.8 ± 0.7 17.9 ± 0.9 38.3 ± 1.9 
PPARα + C16:0 6.6 ± 5.1 6.5 ±  1.4 19.9 ±  6.0 7.5 ±  3.1 11.9 ±  6.1 47.6 ±  8.4 
PPARα + C16:0 -CoA 1.5 ±  0.6 5.4 ±  0.3 26.3 ±  1.4 10.6 ±  0.4 18.6 ±  1.3 37.6 ± 1.3 
PPARα + C18:1 6.0 ± 3.9 5.9 ± 0.6 20.8 ± 4.4 7.6 ± 2.8 12.3 ± 6.2 47.4 ± 8.9 
PPARα + C18:1-CoA 4.8 ± 1.7 6.6 ± 0.9 22.8 ± 1.5 11 ± 0.6 20.2 ± 0.6 34.5 ± 2 
PPARα + C18:2 3.4 ± 1.5 6.3 ± 0.8 23.5 ± 1.4** 10.5 ± 0.9 19.6 ± 1.7 36.8 ± 2.7 
PPARα + C18:2-CoA 3.8 ± 1.6 6.5 ± 0.8 24.1 ± 2.6 10.1 ± 0.8 18.1 ± 0.4 37.4 ± 1.2 
PPARα + C20:5 5.8 ± 4.2 6.1 ± 0.9 21.1 ± 5.5 8 ± 2.9 12.4 ± 6.2 46.7 ± 9.5 
PPARα + C20:5-CoA 5.6 ± 3.3 23.4 ± 14.9 19.2 ± 4.2 8.1 ± 3.5 15.9 ± 5.1 43.7 ± 7.5 
LXRα + solvent 4 ± 1.5 6.1 ± 0.7 21.4 ± 2 10.3 ± 2.1 18.1 ± 2.5 39.7 ± 4.5 
LXRα + C16:0 3.6 ± 4.3 5.4 ± 0.9 21.8 ± 6.8 57.5 ± 29.8 15.7 ± 6 44.3 ± 11.1 
LXRα + C16:0 -CoA 8.5 ± 3.1 7.3 ±  1.1 13 ±  4.4 4.3 ±  4.3 7.2 ±  7.2 59.2 ±  12 
LXRα + C18:1 1 ± 0.4 4.3 ± 0.4 25.1 ± 1.9 12.9 ± 2.0 22.5 ± 3.9 34.3 ± 3.9 
LXRα + C18:1 -CoA 1 ± 0.3 15.7 ± 10.6 22.6 ± 1.9 15.1 ± 0.5 23.4 ± 1.9 33.2 ± 2.1 
LXRα + C18:2 3 ± 0.4 7.2 ± 0.4 24.3 ± 0.9 9.8 ±0.6 19.7 ± 1.2 36.1 ± 1.3 
LXRα + C18:2 -CoA 4.8 ± 2.5 7.1 ± 1.5 20.4 ± 4.5 7.4 ± 3.2 16.2 ± 3 44.1 ± 6.7 
LXRα + C20:5 5.2 ± 2.7 6 ± 1.1 19.3 ± 3.9 8.6 ± 4.4 15.1 ± 6.2 45.9 ± 10.6 
LXRα + C20:5 -CoA 7.5 ± 7.1 5.5 ± 1.8 16.1 ± 8.8 5.8 ± 2.5 10 ± 6.8 55.3 ± 15.7 
Asterisks (*) represent significant differences due to presence of ligand as compared with the no-
ligand for all the panels. *p < 0.05, **p < 0.01, ***p < 0.001. 
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TABLE 4. Secondary structures of hPPARα and hLXRα, individually and as a mixture 
(corrected for solvent effect) in the presence and absence of fatty acids 
        Protein α-helix regular 
α-helix 
distorted 
β-sheet 
regular 
β-sheet 
distorted Turns          Unrd  
  H(r) %     H (d) %     S(r) % S (d) % T%          U%  
PPARα+LXRα+solvent 4.2 ± 2.9 5.3 ±  2.9 14.5 ±  6.1 11.5 ±  6 28 ±  14.6 36.3 ±  11.9 
       
PPARα+16:0 and LXRα (CA) 3.8 ±  1.7 6.4 ± 0.8 23.8 ±  2.4 9.7 ±  0.1 18 ±  1.1 38.1 ±  1.5 
LXRα+16:0 and PPARα (CA) 8 ±  3.7 6.5 ±  0.9 16 ±  6 11.8 ±  2.3 17 ±  51.8 51.8 ±  11 
PPARα+LXRα+16:0 (Exp) 3.7 ±  3 5.5 ±  1 21.4 ±  3.8 9.8 ±  1.9 17.1 ±  2.8 40.8 ±  5.2 
PPARα+16:0 and LXRα+16:0 (CA) 4.3 ±  1.7 6.2 ±  0.6 22.3 ±  2 9.4 ±  1.8 16 ±  3 41.6 ±  5 
       PPARα+18:1 and LXRα (CA) 4.8 ±  3.4 6.3 ±  0.5 22.6 ±  4.5 8.53 ±  2.7 14.2 ±  5.2 43.4 ±  8.5 
LXRα+18:1 and PPARα (CA) 1.3 ±  0.5 4.5 ±  0.4 25 ±  0.5 13 ±  1.5 22.7 ±  3 33.4 ±  4 
PPARα+LXRα+18:1 (Exp) 1.4 ±  0.6 4.8 ±  0.4 23.7 ±  0.3 13.6 ±  1.4 24.1 ±  2.7 32.1 ±  3 
PPARα+18:1 and LXRα+18:1 (CA) 1.3 ±  0.5 5 ±  0.3 26 ±  1 11.7 ±  1.4 19.7 ±  2.1 36.2 ±  2.2 
       PPARα+18:2 and LXRα (CA) 3.5 ±  18 6.3 ±  0.4 23.7 ±  1.7 10 ±  1.3 18 ±  2.5 38.4 ±  3.4 
LXRα+18:2 and PPARα (CA) 1.7 ±  0.7 5 ±  0.4 25.1 ±  0.6 12 ±  0.8 20.7 ±  0.9 35.5 ±  1.4 
PPARα+LXRα+18:2 (Exp) 1 ±  0.4 4.8 ±  0.2 26 ±  1.4 12 ±  1.2 20.3 ±  2.2 35.8 ±  2 
PPARα+18:2 and LXRα+18:2 (CA) 1.7 ±  0.1 5.3 ±  0.1 25.4 ±  0.5 11.4 ±  0.3 20.1 ±  0.8 36 ±  1.3 
       PPARα+20:5 and LXRα (CA) 5.3 ±  3.5 6 ±  0.4 21.9 ±  4.6 8.3 ±  2.7 13 ±  6.2 44.7 ±  9.5 
LXRα+20:5 and PPARα (CA) 1.7 ±  0.6 5.5 ±  0.2 26.3 ±  3.1 11 ±  1.2 18.8 ±  2.6 36.5 ±  1.2 
PPARα+LXRα+20:5 (Exp) 8.4 ±  3.8 6.2 ±  0.4 18.8 ±  5.3 5 ±  2.2 10.6 ±  4.8 56 ±  8.2 
PPARα+20:5 and LXRα+20:5 (CA) 5.4 ±  3 6 ±  0.2 20.7 ±  3.8 14.4 ±  2.8 19.8 ±  0.4 46 ±  10.4 
Exp – Experimental, CA – Calculated Average 
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TABLE 5. Secondary structures of hPPARα and hLXRα, individually and as a mixture 
(corrected for solvent effect) in the presence and absence of fatty acyl CoAs 
        Protein α-helix regular 
α-helix 
distorted 
β-sheet 
regular 
β-sheet 
distorted Turns      Unrd  
  H(r) % H (d) % S(r) % S (d) % T%  U%  
PPARα+LXRα+solvent  4.2 ± 2.9 5.3 ±  2.9 14.5 ±  6.1 11.5 ±  6 28 ±  14.6 36.3 ±  11.9 
       PPARα+16:0-CoA and LXRα (CA) 5 ± 1.8 7 ± 0.7 21.4 ± 2.5 9.9 ± 1.1 18.7 ± 1.7 37.9 ± 3.1 
LXRα+16:0-CoA and PPARα (CA) 8.9 ± 3.3 6.6 ± 0.5 15.8 ± 5.1 5.8 ± 3.3 13.7 ± 5.6 55.3 ± 11 
PPARα+16:0-CoA and LXRα+16:0-CoA 
(CA) 5.8 ± 1.7 7.2 ±  0.9 20 ±  2.4 7.3 ±  2.7 10.5 ±  6 48.4 ±  7.4 
PPARα+LXRα+16:0-CoA (Exp) 3.1 ± 2.3 5.5 ± 0.8 23.1 ± 3.4 9.8 ± 2 16.4 ± 3.1 41.9 ± 4.7 
       PPARα+18:1-CoA and LXRα (CA) 5.6 ± 2.1 7.7 ±  0.4 21.8 ± 3.1 10.4 ± 1.6 18.3 ±  3 35.7 ±  5.7 
LXRα+18:1-CoA and PPARα (CA) 1.7 ±  0.3 5.3 ± 0.2 25.4 ±  1.6 13 ± 0.3 21 ±  0.2 33.4 ±  1.9 
PPARα+18:1-CoA and LXRα+18:1-CoA 
(CA) 2.5 ±  0.5 5.7 ±  0.4 24.8 ±  0.6 13.3 ±  0.1 21.7 ±  0.5 31.87 ± 0.9 
PPARα+LXRα+18:1-CoA (Exp) 4.9 ± 1.5 6.8 ± 0.9 21.3 ± 2.2 9.3 ± 2.3 17.9 ±3 39.5 ± 5.2 
       PPARα+18:2-CoA and LXRα (CA) 4.5 ± 2.1 7.2 ± 0.6 22.5 ± 3.5 9.7 ± 0.9 19.2 ± 1.6 36.7 ± 3.3 
LXRα+18:2-CoA and PPARα (CA) 5.9 ± 3 6.2 ± 0.3 21 ± 3.9 8.5 ± 3.1 19.5 ± 0.4 45.3 ± 10 
PPARα+18:2-CoA and LXRα+18:2-CoA 
(CA) 6.6 ± 2.7 7 ± 0.7 19.3 ± 3.3 7.9 ± 2.5 14.4 ± 4.9 44.5 ± 7.8 
PPARα+LXRα+18:2-CoA (Exp) 5.2 ± 3.5 5.5 ± 1 20.2 ± 4.7 8.3 ± 4.4 12.9 ± 6.5 47.5 ± 10 
       PPARα+20:5-CoA and LXRα (CA) 5.1 ± 1.7 7.3 ± 0.2 21.6 ± 2.9 10.4 ± 1.7 18.9 ± 2.7 36.5 ± 5.4 
LXRα+20:5-CoA and PPARα (CA) 6.2 ± 3.5 7.1 ± 0.8 18.5 ± 2.6 6 ± 1.9 11.1 ± 3.3 50.2 ± 4.5 
PPARα+20:5-CoA and LXRα+20:5-CoA 
(CA) 7.5 ± 3.7 6.5 ± 1.1 16.5 ± 4.1 7.7 ± 4 11.6 ± 6 51.1 ± 8.7 
PPARα+LXRα+20:5-CoA (Exp) 1.6 ± 0.4 4.7 ± 0.6 24.3 ± 0.5 12.6 ± 1.1 22.5 ± 1.5 34.1 ± 2.2 
Exp – Experimental, CA – Calculated Average 
 
39 
 
Cy5-hPPARα and hLXRα interact with a strong binding affinity  
 
As the CD spectrum only shows a change in conformation, and cannot completely 
determine if the conformational change is due to an efficient interaction with the other 
protein or ligand, binding assays were conducted with hPPARα and hLXRα in the 
presence and absence of ligands to determine the binding affinity. 
 
While the CD spectra of the mixture of the hPPARα and hLXRα suggested a 
possible interaction, the direct binding assay of Cy5 labeled hPPARα and hLXRα further 
confirmed high affinity binding of the two proteins, with binding affinities in the 
nanomolar range.  A titration of Cy5-hPPARα against an increasing concentration of 
hLXRα ranging from 0nM to 250nM resulted in strong saturable binding and very high 
affinity binding (Kd = 6±2nM, Figure 8C), and the double reciprocal plot (inset) further 
suggested a single binding site.  In order to ensure that the two proteins directly interact 
and that the results obtained were not an artifact of the fluorophore added to the PPARα 
protein, Cy3 labeled hLXRα protein was also titrated with GR protein.  While increasing 
concentrations of GR resulted in increased fluorescence intensity, the shape of the curve 
was non-saturable and almost linear (Figure 8B), suggesting only nonspecific binding (Kd 
> 270nM).  To further ensure that the binding of hPPARα and hLXRα was due to true 
protein-protein interaction, Cy3 labeled hLXRα was titrated with increasing 
concentrations of hPPARα (Figure 8A).  This titration resulted in strong saturable binding 
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(Figure 8C), although with slightly lower affinity (Kd = 42±16nM), further confirming 
the binding of hPPARα and hLXRα.   
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FIGURE 8: Fluorescent binding assays with labeled protein titrated against increasing 
concentrations of unlabeled protein. (A) 25nM of Cy3hLXRα was titrated against increasing 
concentrations of 0nM to 250nM hPPARα. The x-axis represents the concentration of hPPARα 
used and the y-axis represents the change in fluorescence intensity. (B) 25nM of Cy3hLXRα was 
titrated against increasing concentrations of 0nM to 250nM hGR. The x-axis represents the 
concentration of hGR used and the y-axis represents the change in fluorescence intensity. (C) 
25nM of Cy5hPPARα was titrated against increasing concentrations of 0nM to 250nM hLXRα. 
The x-axis represents the concentration of hLXRα used and the y-axis represents the change in 
fluorescence intensity. Insets represent double reciprocal linear plots of each binding curve. 
Values represent mean ± SE; n = 3-6 
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hPPARα and hLXRα Binding in presence of Ligands 
 
After confirming the direct binding of hPPARα and hLXRα with high affinity, the 
effects of fatty acids and their CoA thioesters such as palmitic acid, palmitoyl-CoA, oleic 
acid, oleoyl-CoA, linoleic acid, linoleoyl-CoA, EPA and EPA-CoA on the binding 
affinity were examined.  While the saturated fatty acid – palmitic acid (Figure 9A) did 
not affect the interaction between Cy5hPPARα and hLXR and displayed a similar Kd of 
7±2nM as that of the two proteins in the absence of a ligand (Figure 8C), its CoA 
thioester palmitoyl-CoA (Figure 9B) slightly decreased the binding affinity yielding a Kd 
of 53±17nM.  On the other hand, the unsaturated fatty acid – oleic acid (Figure 9C) 
marginally decreased the binding of the two proteins with a Kd of 37±10nM, when 
compared to its CoA form- oleoyl-CoA (Figure 9D) that displayed a binding affinity of 
27±12nM.   
Further assays with polyunsaturated fatty acids, linoleic acid and EPA, showed  
decreased binding of Cy5hPPARα and hLXRα suggesting that the fatty acids may 
interact with one or both of the proteins causing a conformational change such that the 
binding ability is altered.  While linoleic acid (Figure 10A) decreased the binding 
affinity, yielding an increased Kd of 151±93nM, EPA (Figure 10C) strongly decreased 
the binding and resulting in a Kd greater than 600nM.  The CoA thioesters of the two 
fatty acids also decreased the binding affinity; while the Kd of 36±11nM displayed by 
linoleoyl CoA (Figure 10B) was much similar to that of oleic acid, EPA-CoA (Figure 
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10D) caused a large change in interaction between the proteins, and generated a Kd of 
135±160nM suggesting an interference with the binding.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 9: Binding curves of the change in fluorescent intensity (Fo-F) of a mixture of 
equal concentrations of the fluorescently labeled Cy5hPPARα and the ligand titrated with 
increasing concentrations of hLXRα. Binding curves of 25nM Cy5hPPARα titrated against 
hLXRα in the presence of 25nM of ligands (A) palmitic acid, (B) its CoA thioester – palmitoyl 
CoA, (C) Oleic acid and (D) Oleoyl-CoA 
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FIGURE 10: Binding curves of the change in fluorescent intensity (Fo-F) of a mixture of 
equal concentrations of the fluorescently labeled Cy5hPPARα and the ligand titrated with 
increasing concentrations of hLXRα. Binding curves of 25nM Cy5hPPARα titrated against 
hLXRα in the presence of 25nM of ligands (A) linoleic acid, (B) linoleoyl-CoA, (C) EPA and (D) 
EPA-CoA.  
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Co-Immunoprecipitation: PPARα and LXRα show direct interaction in mouse liver 
homogenates 
 
After the interactions and binding of the two recombinant nuclear receptors, 
hPPARα and hLXRα, were observed in vitro with circular dichroism and binding assays, 
the interaction between PPARα and LXRα was tested in vivo.  Co-immunoprecipitation 
of liver samples with PPARα or LXRα antibodies, and subsequent Western blot analysis 
for PPARα (Figure 10A) or LXRα (Figure 10B) protein, resulted in bands corresponding 
to 50kDa for liver homogenate and each antibody linked  resin, further suggesting a 
direct interaction of PPARα and LXRα.  The bands in both PPARα (Figure 11A) and 
LXRα (Figure 11B) Western blots show strong bands, however at a slightly higher 
molecular weight than 50kDa.  This shift in the bands could be due to post-translational 
modifications of the proteins that occur endogenously.  As a control, elute obtained from 
resin coupled with no antibodies was run along with the other samples in order to confirm 
that the binding of the proteins to their antibodies was not just an artifact.  The lane with 
elute obtained from resin with no antibody did not show any bands, further confirming 
the antibody-specific binding of the proteins.  
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  FIGURE 11:  CoIP assay using wild type mouse liver sample showing interaction of 
PPAR and LXR. (A)Western of a mouse liver sample passed through resin coupled with 
PPARα- and LXRα-antibody and treated with PPARα antibody. (B) Western of a mouse liver 
sample passed through resin coupled with PPARα- and LXRα-antibody and treated with LXRα 
antibody. 
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Transactivation Assay 
 
In order to determine the significance of these findings, the ability of the PPARα 
ligands palmitic acid, oleic acid, linoleic acid and EPA to affect either a PPARα regulated 
gene (acyl-CoA oxidase, ACOX) or an LXRα regulated gene (SREBP) was examined.  
ACOX is known to play a role in fatty acid metabolism, while SREBP regulates 
cholesterol metabolism [61].  Activity was measured with a reporter construct for 
luciferase expression, and the relative amount of luciferase produced in the presence of 
clofibrate, palmitic acid, oleic acid, linoleic acid and EPA was compared to the activity of 
the two proteins in the absence of ligands.  Four concentrations (1µM, 5µM, 10µM and 
20µM) of each ligand were tested for the effect on relative PPARα or LXRα activity.  
 
The transactivation of the PPARα gene ACOX was fairly consistent throughout, 
both in the groups treated with no ligand as well as those treated with ligands.  In all 
instances, the presence of both PPARα and LXRα (diamond bars) showed higher activity 
than either PPARα (open bars) or LXRα (forward hash bars) alone, although the extent of 
this affect was ligand dependent (Figure 12).  This suggested that PPARα and LXRα 
heterodimerization could increase PPARα regulated transactivation.  While lower 
concentrations of the ligands palmitic acid, oleic acid, linoleic acid and EPA (1µM, 
Figure 12A and 5µM, Figure 12B) did not seem to affect the expression of ACOX, the 
higher ranges (10µM, Figure 12C and 20µM, Figure 12D) of palmitic acid and oleic acid 
slightly increased the expression.  Furthermore, cells treated with pSG5 (backward hash 
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bars) showed consistent luciferace expression, representing the effect of basal level 
expression of PPARα in HepG2 cells. 
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FIGURE 12: Transactivation of the PPARα regulated gene – ACOX in the absence and 
presence of different concentrations (1µM, 5µM, 10µM and 20µM) of fatty acids (palmitic 
acid, oleic acid, linoleic acid and EPA). The x-axis represents the different ligands plotted 
against the percentage change in activity of ACOX gene on y axis.  (A) 1µM; (B) 5µM; (C) 
10µM and (D) 20µM. Asterisks (*) represent significant differences due to different ligand 
concentrations as compared with the no-ligand for all the panels. *p < 0.05, **p < 0.01, ***p < 
0.001. 
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To further examine the effects of the ligands on the LXR regulated gene – 
SREBP, the transactivation assay was repeated with an SREBP promoter upstream of 
luciferase gene in the presence and absence of all four ligands.  For comparisons between 
PPARα and LXRα regulation, activity was measured by normalizing all values to the 
sample with ACOX and clofibrate.  The cells treated with no ligand showed positive 
activity, with LXRα having the most activity and PPARα the least.  Also, the activity of 
luciferase in cells transfected with PPARα (open bars) remained basal, and cells 
expressing LXRα (forward hash bars) showed an increased activity in all four groups 
tested with 1µM (Figure 13 A), 5µM (Figure 13 B), 10µM (Figure 13 C) and 20µM 
(Figure 13D) ligand concentration.  However, in the presence of all four ligand 
concentrations, the cells transfected with both PPARα and LXRα showed decreased 
activity, indicating that PPARα could possibly play a role in down regulating LXRα 
genes at these given concentrations.  
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FIGURE 13: Transactivation of the LXRα regulated gene – SREBP in the absence and 
presence of different concentrations (1µM, 5µM, 10µM and 20µM) of fatty acids (palmitic 
acid, oleic acid, linoleic acid and EPA). The x-axis represents the different ligands plotted 
against the percentage change in activity of SREBP gene on y axis.  (A) 1µM; (B) 5µM; (C) 
10µM and (D) 20µM. Asterisks (*) represent significant differences due to different ligand 
concentrations as compared with the no-ligand for all the panels. *p < 0.05, **p < 0.01, ***p < 
0.001. 
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V. DISCUSSION 
 
PPARα and LXRα have been known to play a very important role in maintaining 
energy homeostasis and metabolism.  As with any other protein, the stability and the 
function of a protein depends on its secondary structure, and therefore any change in the 
structural conformation may lead to an improper folding resulting in a change in its 
function.  Similarly, with PPARα and LXRα, change in the structure or function of the 
protein may influence the normal functioning and result in an imbalance.  It is therefore 
important to understand the effects of protein-protein or protein-ligand interaction on the 
structure and the function of the proteins.  For example, PPARs have been known to bind 
LCFAs and LCFA-CoAs [39] and regulate genes involved in fatty acid metabolism by 
forming heterodimers with other nuclear receptors such as RXR [36, 62].  Similarly, the 
other nuclear receptor: LXR, activated by sterols is known to regulate cholesterol 
metabolism and dimerizes with its partner – RXR [52, 53].   
 
While PPARα and LXRα have been known to communicate, and regulate each 
other’s activity [54, 55], their direct interactions had not been completely elucidated.  
Furthermore, previous studies largely used either murine, tagged or truncated forms of 
these proteins [39, 63, 64].  Studies suggest that the truncated or tagged forms of nuclear 
receptors function differently when compared to the full length form, in terms of binding 
to ligand or recruitment of cofactors [65].   This study, therefore examined the ability of 
the two full-length proteins, hPPARα and hLXRα to directly interact with each other, and 
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to study the effects of several saturated and unsaturated fatty acids and their CoA 
thioesters on their interaction and function.   
 
A circular dichroic spectrum of a mixture of recombinant, full-length human 
PPARα and LXRα showed a change in the secondary structure, and also suggested the 
possibility of an interaction.  Fluorescent binding assays, further confirmed this 
interaction and for the first time showed high affinity binding of hPPARα and hLXRα 
with Kds in the low nanomolar range.  Furthermore, a coimmunoprecipitation assay using 
mouse liver homogenate showed that both PPARα and LXRα had the capacity to pull 
down the other protein further confirming the interaction of the two proteins in vivo.  This 
interaction between the two proteins suggested that in addition to regulating each other 
indirectly (as suggested by Ide et. al) [2, 3], they could also interact directly and regulate 
genes involved in either fatty acid or cholesterol metabolism.  The finding in this study 
opens up a galore of questions as to what pathway the heterodimer partners would 
regulate, and the factors governing the choice of the pathway they regulate.   
 
Since ligand binding induces structural changes in these receptors, ligand binding 
may also alter protein-protein interactions and/or protein-DNA interactions, which could 
in turn alter gene regulation.  This observation, and the finding that hPPARα and hLXRα 
directly interact, led to the second hypothesis that the known ligands for PPARα (fatty 
acids and their CoA thioesters) could play a role in the interaction of hPPARα and 
hLXRα.  Therefore, circular dichroic spectral analysis of hPPARα and hLXRα as a 
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mixture and individually, were examined in the presence and absence of four different 
fatty acids and their CoA thioesters.  Also, binding assays with a mixture of hPPARα and 
hLXRα were conducted in the presence of all four fatty acids and their CoA thioesters.  
While the CD spectral analysis showed changes in the secondary structure of the 
individual proteins in the presence of fatty acids and their CoAs, it suggested that the 
presence of such ligands could have an effect on the function as well.  Although none of 
the examined ligands increased the interaction of hPPARα and hLXRα, several of the 
ligands had little or no effect, while others severely decreased the interaction of these 
proteins.  This could suggest that in the presence of palmitic acid, oleic acid, oleoyl-CoA, 
and linoleoyl-CoA, hPPARα will readily heterodimerize with hLXRa – perhaps 
preferentially over hRXRα.  For example, a mixture of hPPARα and hLXRα in the 
presence of palmitic acid (saturated) suggested that it does not interfere with the protein-
protein interaction; further confirmed by binding studies that generated a Kd of 7±2nM, 
which is close to the binding affinity obtained in the absence of the ligands.  This could 
mean that the presence of palmitic acid may not hinder hPPARα and hLXRα 
heterodimerization and also the metabolic pathway that they regulate.  However, its CoA 
thioester – palmitoyl CoA showed a small decrease in binding (Kd of 53±17nM) 
correlating to the structural change observed on CD, which could have an effect on the 
downstream genes that PPARα or LXRα regulate.  Moreover, since several of the 
examined ligands (linoleic, EPA, EPA-CoA) strongly decreased the affinity the proteins 
showed for each other, in the presence of these ligands, PPARα may prefer to bind to its 
other heterodimeric partner (RXRα), rather than LXRα.  This choice of heterodimeric 
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partner could in turn determine which response elements will be bound, and in turn 
determine which pathways will be up or down regulated. 
 
The transactivation assay data suggested that the four ligands – palmitic acid, 
oleic acid, linoleic acid and EPA did not significantly alter the expression of the PPARα-
regulated gene ACOX in the presence of the heterodimer partner LXRα, suggesting that 
they might not affect fatty acid metabolism.  It is however possible that the ligand 
concentrations used are not optimal for PPARα-LXRα activation, that LXRα might not 
be a preferred partner for heterodimerization in the presence of these fatty acids, or that 
PPARα heterodimerization to LXRα results in weaker binding to the PPRE of the acyl-
CoA oxidase gene than when heterodimerized to RXRα (although still stronger than 
PPARα alone).  On the other hand, cells transfected with the SREBP promoter showed a 
decrease in luciferase activity in the presence of both PPARα and LXRα indicating that 
the interaction of PPARα with LXRα decreases the expression of this LXRα-activated 
gene.   
 
While saturated and unsaturated fatty acids are required by the body in moderate 
levels to perform normal functions, an excess will lead to imbalance. Previous studies 
have shown that the saturated fatty acid, palmitic acid is known to elevate cholesterol 
levels and also increase the risk of coronary heart diseases [66, 67].  However, these fatty 
acids are required to perform vital roles in lipogenesis, fat deposition and polyunsaturated 
fatty acids bioavailability in the cells [68].  In this current study, data from transactivation 
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assay shows that the presence of palmitic acid does not affect PPARα from interacting 
with LXRα.  The results therefore indicate the possibility of PPAR-LXR heterodimer in 
decreasing LXRs ability to upregulate SREBP gene, which is involved in cholesterol 
metabolism.  Therefore, palmitic acid decreases SREBP activity, and lowers cholesterol 
synthesis.  Although the unsaturated fatty acids, oleic acid, linoleic acid and EPA affect 
PPARα and LXRα heterodimerization, they also decrease SREBP activity suggesting that 
a diet rich in fatty acids might help in reducing cholesterol.  However, cholesterol is an 
important precursor to essential components such as steroids, vitamin D and bile.  In the 
presence of high levels of cholesterol, PPARα-LXRα heterodimer is favored; however in 
presence of low levels of cholesterol, LXRα might preferentially bind to its partner RXR 
to activate cholesterol synthesis.    
 
In summary, this is the first study to show not only direct interaction between full 
length human PPARα and LXRα, but also the effects of ligands on the binding and 
function of the two proteins.  
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LIST OF ABBREVIATIONS 
 
ACOX - acyl-CoA oxidase 
CPT1A - carnitine palmitoyl transferase 1A 
DBD – DNA binding domain 
DTT – Dithiothreitol 
EDTA – Ethylene di amine tetra acetic acid 
FAS – Fatty acyl synthase 
FXR – Farsenoid X receptor 
GLUT1 - glucose transporter 
HRE – Hormone response elements 
LBD – Ligand binding domain 
LCFA – Long chain fatty acid 
LCFA-CoA – Long chain fatty acyl CoA 
L-FABP - liver-fatty acid binding protein 
LXR – Liver X receptor 
LXRE – Liver X receptor response elements 
PPAR – peroxisome proliferator activated receptor 
PPRE – peroxisome proliferator response elements 
RXR – Retenoid X receptor 
SDS – Sodium dodecyl sulphate 
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